Eric Fitzsimmons

The FDA approved the use of pembrolizumab (Keytruda) to treat some early-stage, triple-negative breast cancers, marking the first time an immunotherapy medicine has been approved for use in early-stage breast cancer.

There are many ways to make healthier food choices, but it can be hard to know where to start. We spoke to cancer nutrition and fitness expert Stacy Kennedy, MPH, RD, CSO, LDN, CPT, about what you can do if you’ve just resolved to start a healthier diet.

Read More

 | 10 Min. Read |   17

Lilly Bolen built an annual fundraiser around live sports at Tuft’s University, but even with in-person events canceled, Bolen and other supporters turned out to raise $25,000.

For people affected by breast cancer, the holidays can be difficult every year. As experts caution against large events, traveling, and indoor gatherings for the 2020 season, the way we celebrate this year will be different than we are used to, and that can make this time even more upsetting.

Two studies, presented as part of the 2020 ASCO Annual Meeting, provide guidance on how medicines approved in the past few years are best used in combination and after other treatments.

The PHERGain trial, presented May 29 as part of the 2020 ASCO Annual Meeting, explored using PET scans to select people with early-stage HER2-positive breast cancer who may not need chemotherapy.

Adding a year of capecitabine (Xeloda) after standard treatment resulted in fewer people with early-stage, triple-negative breast cancer having a recurrence, according to a study presented at the 2020 ASCO Annual Meeting.

Read More

 | 6 Min. Read |   1

A randomized trial of women with de novo metastatic breast cancer found that surgery and radiation to remove the primary tumor did not lead to longer survival.

A new analysis of the HER2CLIMB trial found that adding tucatinib (Tukysa) to treatment for people with stage IV HER2-positive breast cancer prevents brain metastases from growing.

Roberta "Bobbi" Albany spoke with LBBC about her experience with sexual side effects, techniques she’s found that help, and what is needed to help women with breast cancer.

Read More

 | 11 Min. Read |   4

How the COVID-19 pandemic affected breast cancer care, from surgery to radiation to chemotherapy/targeted therapy to fertility preservation.

The antibody-drug conjugate sacituzumab govitecan (Trodelvy) is now approved to treat people with metastatic, triple-negative breast cancer that has grown after past lines of treatment.

The Food and Drug Administration approved the targeted medicine tucatinib (Tukysa) to be used in treatment for people with metastatic HER2-positive breast cancer.

Drs. Julie Gralow and Reshma Mahtani explain how people in treatment for breast cancer can balance the known threat of breast cancer against what was known about the potential threat of developing COVID-19 in the first few months of the pandemic.

Tyrosine kinase inhibitor showed longer survival for people with metastatic HER2-positive breast cancer already given multiple lines of treatment.

FDA names tucatinib a breakthrough therapy and grants accelerated approval to trastuzumab deruxtecan in weeks after San Antonio Breast Cancer Symposium.

Studies presented at San Antonio Breast Cancer Symposium try to find complete responses to neoadjuvant therapy without surgery, but current options fall short.

In phase III trial, paclitaxel pills got higher response rates with lower rates of neuropathy when given with encequidar for metastatic breast cancer.

Updates from a recent study show improvements in pathological complete response affect women with different personal and tumor features.

Researchers recommend considering risk and benefits when considering extended treatment.

Read More

 | 5 Min. Read |   1

Trastuzumab durextecan (Enhertu) was FDA approved to treat HER2-positive metastatic breast cancer in December 2019. This article explains the research that helped support the initial FDA approval.

Given with trastuzumab and capecitabine, tucatinib also led to longer progression-free survival and improved outcomes for people with brain metastases.

Ribociclib (Kisqali) and abemaciclib (Verzenio) show longer overall survival for people with certain hormone receptor-positive breast cancers, makers announce

Allergan announced on July 24 that it is voluntarily recalling breast implants with its Biocell textured surface. The implants have been linked to a rare cancer called breast implant-associated anaplastic large cell lymphoma.

A study showed positive results for people with metastatic triple-negative breast cancer taking sacituzumab govitecan.

The addition of the CDK 4/6 inhibitor ribociclib (Kisqali) to hormonal therapy for premenopausal women with metastatic, hormone-receptor positive breast cancer, resulted in women living longer than they would if given hormonal therapy alone.

Positive results for new applications of two existing biomarker tests; researchers hope these new ways of applying the tests will help direct treatments to people who need them, and spare people who won’t benefit.

New results from the Women’s Health Initiative Dietary Modification trial show that postmenopausal women directed to a low-fat diet were less likely to die of breast cancer.

A study of 4,262 people with early-stage breast cancer presented at the 2019 ASCO Annual Meeting sought to define how chemotherapy and hormonal therapy affect quality of life.

The U.S. Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) to treat certain people with early-stage, HER2-positive breast cancers.

Comorbidities present unique challenges in treating older adults with breast cancer.

Read More

 | 11 Min. Read |   1

At the 2018 San Antonio Breast Cancer Symposium, researchers discussed how young women make decisions about breast surgery, as well as age-related breast cancer risks

Medicines approved for other uses were shown to protect the heart from side effects of trastuzumab, or Herceptin, a widely used medicine in HER2-positive breast cancer.

Read More

|   1

Findings announced at the San Antonio Breast Cancer Symposium offer more evidence that continuing hormonal therapy after five years prevents recurrences.

Read More

|   1

If you are considering medical marijuana, there are important questions you should ask — about the law, about your treatment, about yourself and about medical marijuana — before you begin.

Read More

 | 12 Min. Read |   2

Four women share their impressions of Breast Cancer Awareness Month: what is good about it, what they hope for it and what frustrates them.

Read about the latest breast cancer research presented at the 2018 American Society of Clinical Oncology meeting.

Pertuzumab can be added to trastuzumab and chemotherapy for people at high risk of recurrence

In order to pay for treatment, people may have to go into debt, refinance their home, delay other major expenses and make major changes to their lifestyle.

Clinical trials are studies carried out in people to learn more about diseases, like breast cancer, and their treatments. Clinical trials for breast cancer often explore new approaches to treatment.

The San Antonio Breast Cancer Symposium is a chance for experts and patient advocates from around the world to come together and discuss updates in treatment and care for people with breast cancer. The 40th annual SABCS is being held December 5 ­– 9, 2017.

Adding the targeted therapy pertuzumab (Perjeta) to standard anti-HER2 treatment for early-stage, HER2-positive breast cancer resulted in more people living at least 3 years without a recurrence.

The Food and Drug Administration has approved abemaciclib (Verzenio), both on its own and in combination with fulvestrant (Faslodex), to treat hormone receptor-positive metastatic breast cancers after other treatments have stopped working.

Many factors go into deciding how to treat breast cancer. A comorbidity, a condition you have in addition to breast cancer, can make that decision even more complex.

Women with breast cancer tend to have better outcomes when they have a bigger network of friends, family and other social connections, but different types of social support were important for different women.

Most cancers are caused by mutations that happen during a person’s life. But some mutations pass from parent to child and put people at higher risk for breast cancer. An estimated 5 to 10 percent of breast cancers are linked to mutations on the most well-known breast cancer-associated genes, the BRCA genes.

Stressful life events, like a cancer diagnosis, put people who have been diagnosed with depression or another mood or anxiety disorder at a higher risk of experiencing an episode related to that disorder.

Metastatic breast cancer may cause you to feel anticipatory grief — sadness about things you expect to lose in the future, like your energy, your independence, your job, your financial stability, and ultimately, your life.

Everyone who has been diagnosed with breast cancer faces the fear of recurrence. For many it is an ongoing concern, and for some it can interfere with enjoying daily life.

Women taking hormonal therapy for breast cancer who received financial assistance for their medicine were more likely to stay on that medicine, regardless of race or ethnicity, than women who did not.

The American Society for Radiation Oncology (ASTRO) released new guidelines for the use of accelerated partial-breast radiation to treat early-stage breast cancer that opens the door for more people to get this treatment.

MammaPrint, a test that looks at 70 genes in a breast cancer tumor, may be used to help some women with early-stage disease avoid chemotherapy.

Chemotherapy is known for causing side effects, from hair loss to nausea to heart damage to neuropathy. Who gets chemotherapy has changed in recent years, but for many people with breast cancer, chemotherapy is still standard treatment.

Read More

 | 12 Min. Read |   1

A study found that within 2 years of diagnosis, most women who have had DCIS enjoyed a quality of life similar to that of peers who had no cancer. But it also showed a trend to worse mental well-being in younger women shortly after diagnosis and all women 10 or more years after diagnosis.